These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32382359)

  • 61. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome.
    Ritmeijer K; Veeken H; Melaku Y; Leal G; Amsalu R; Seaman J; Davidson RN
    Trans R Soc Trop Med Hyg; 2001; 95(6):668-72. PubMed ID: 11816442
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Magnitude of visceral leishmaniasis and poor treatment outcome among HIV patients: meta-analysis and systematic review.
    Alemayehu M; Wubshet M; Mesfin N
    HIV AIDS (Auckl); 2016; 8():75-81. PubMed ID: 27042142
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Leishmaniases and HIV/AIDS co-infections: review of common features and management experiences.
    Ali A
    Ethiop Med J; 2002 Apr; 40 Suppl 1():37-49. PubMed ID: 12802830
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Characterization of visceral leishmaniasis outbreak, Marsabit County, Kenya, 2014.
    Kanyina EW
    BMC Public Health; 2020 Apr; 20(1):446. PubMed ID: 32248804
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical and laboratory profiles of visceral leishmaniasis among adult patients admitted to Felege Hiwot Hospital, Bahir Dar, Ethiopia.
    Tarekegn B; Tamene A
    SAGE Open Med; 2021; 9():20503121211036787. PubMed ID: 34377476
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia.
    Diro E; Blesson S; Edwards T; Ritmeijer K; Fikre H; Admassu H; Kibret A; Ellis SJ; Bardonneau C; Zijlstra EE; Soipei P; Mutinda B; Omollo R; Kimutai R; Omwalo G; Wasunna M; Tadesse F; Alves F; Strub-Wourgaft N; Hailu A; Alexander N; Alvar J
    PLoS Negl Trop Dis; 2019 Jan; 13(1):e0006988. PubMed ID: 30653490
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Visceral leishmaniasis: a comparative study of patients with and without human immunodeficiency virus infection].
    Reus S; Sánchez R; Portilla J; Boix V; Priego M; Merino E; Román F
    Enferm Infecc Microbiol Clin; 1999 Dec; 17(10):515-20. PubMed ID: 10650648
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia.
    Hurissa Z; Gebre-Silassie S; Hailu W; Tefera T; Lalloo DG; Cuevas LE; Hailu A
    Trop Med Int Health; 2010 Jul; 15(7):848-55. PubMed ID: 20487426
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
    Molina I; Falcó V; Crespo M; Riera C; Ribera E; Curran A; Carrio J; Diaz M; Villar del Saz S; Fisa R; López-Chejade P; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Oct; 60(4):837-42. PubMed ID: 17684055
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Assessment of a recombinant protein from Leishmania infantum as a novel tool for Visceral Leishmaniasis (VL) diagnosis in VL/HIV co-infection cases.
    Ramos REM; Santos WJT; Magalhães FB; Diniz GTN; Costa CHN; de Melo Neto OP; Medeiros ZM; Reis CRS
    PLoS One; 2021; 16(5):e0251861. PubMed ID: 33999968
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Development of a sandwich ELISA to detect Leishmania 40S ribosomal protein S12 antigen from blood samples of visceral leishmaniasis patients.
    Zhang WW; Ghosh AK; Mohamath R; Whittle J; Picone A; Lypaczewski P; Ndao M; Howard RF; Das P; Reed SG; Matlashewski G
    BMC Infect Dis; 2018 Oct; 18(1):500. PubMed ID: 30285653
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Implications of co-infection of Leptomonas in visceral leishmaniasis in India.
    Selvapandiyan A; Ahuja K; Puri N; Krishnan A
    Parasitology; 2015 Dec; 142(14):1657-62. PubMed ID: 26492813
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia.
    Tamiru A; Tigabu B; Yifru S; Diro E; Hailu A
    BMC Infect Dis; 2016 Oct; 16(1):548. PubMed ID: 27724891
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India.
    Sinha PK; van Griensven J; Pandey K; Kumar N; Verma N; Mahajan R; Kumar P; Kumar R; Das P; Mitra G; Flevaud L; Ferreyra C; Remartinez D; Pece M; Palma PP
    Clin Infect Dis; 2011 Oct; 53(7):e91-8. PubMed ID: 21890763
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy.
    Mira JA; Corzo JE; Rivero A; Macias J; De Leon FL; Torre-Cisneros J; Gomez-Mateos J; Jurado R; Pineda JA
    Am J Trop Med Hyg; 2004 Mar; 70(3):298-301. PubMed ID: 15031520
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Noninvasive Diagnosis of Visceral Leishmaniasis: Development and Evaluation of Two Urine-Based Immunoassays for Detection of Leishmania donovani Infection in India.
    Ejazi SA; Bhattacharya P; Bakhteyar MA; Mumtaz AA; Pandey K; Das VN; Das P; Rahaman M; Goswami RP; Ali N
    PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005035. PubMed ID: 27741241
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Visceral leishmaniasis treatment outcome and its determinants in northwest Ethiopia.
    Welay GM; Alene KA; Dachew BA
    Epidemiol Health; 2016; 39():e2017001. PubMed ID: 28092934
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Visceral leishmaniasis in northern Ethiopia.
    Haile T; Anderson SD
    East Afr Med J; 2006 Jul; 83(7):389-92. PubMed ID: 17089499
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Visceral leishmaniasis in immunocompromised patients].
    Ramos A; Portero JL; Gazapo T; Yebra M; Portero F; Martín T
    An Med Interna; 1998 Jun; 15(6):301-4. PubMed ID: 9656509
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
    Rai K; Cuypers B; Bhattarai NR; Uranw S; Berg M; Ostyn B; Dujardin JC; Rijal S; Vanaerschot M
    mBio; 2013 Oct; 4(5):e00611-13. PubMed ID: 24105765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.